"With all of MorphoSys’ Phase 3 clinical programs now fully enrolled and additional cost optimization measures planned, MorphoSys’ anticipated 2024 operating expenses are expected to be lower compared to 2023. As a result, the company expects an anticipated 2024 cash burn of approximately € 250 million (excluding debt and interest payments).
Thanks for sharing that article jerry. Morphosys is a little further advanced in their programs that Patrys but it does illustrate the appetite by big pharma for acquisitions.
2024 An Eventful Year, page-26
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.229M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $5.431K | 1.357M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 26519870 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7889760 | 12 |
View Market Depth
| Last trade - 11.23am 15/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |